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Endovascular repair of thoracic and thoraco-abdominal aortic lesions
BACKGROUND: We report our “real-world” experience of endovascular repair of thoracic/thoraco-abdominal aortic lesions
in patients treated from May 2002 to May 2017. 
METHODS: Data of all consecutive treated patients were retrospectively collected in a database and analyzed. Patients
were divided into 4 groups: atherosclerotic thoracic/thoraco-abdominal aneurysms (TAA/TAAA) and floating thrombus
(group A); acute complicated type B dissection (TBD), penetrating aortic ulcers (PAU) and intra-mural hematomas
(IMH) in group B; chronic TBD evolving in TAA (group C); traumatic injuries (group D). Mortality, reinterventions
and occurrence of neurological complications, both at 30 days and in the long term, were analyzed as primary outcomes
for each group. 
RESULTS: Ninety-four patients were treated complessively, most for a TAA (55.3%). Thirty-days deaths and neurological
complications were observed in group A only (5 cases each, 5.3%). A reintervention was necessary in 6 patients (6.4%)
of group A. At 5 years, in group A survival was 62.8%±6.3% and freedom from neurological complication was
88.3%±4.2%. Neither deaths nor neurological complications were recorded in the other groups. No late aortic ruptures
were recorded. Freedom from reintervention in group A was 54.7%±7.6% at 5 years and a reintervention was need-
ed in all patients of group D. Overall, the main cause for reintervention was a type I endoleak. 
CONCLUSIONS: The endovascular repair of thoracic/thoraco-abdominal aortic lesions had acceptable mortality and neuro-
logical complication rates, both at 30 days and in the long term. Reinterventions in the long term occurred more fre-
quently after TAA/TAAA and traumatic injuries, and were mainly required for a type I endoleak. 
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ment of thoracic aortic lesions (TEVAR), overcoming
the open techniques with the advantage of reduced post-
operative mortality and morbidity 2,3.
On the other hand, thanks to the improvement of mate-
rials, they have recently been extended to complex seg-
ments such as the thoraco-abdominal region, making it
possible to treat “high risk patients” that previously
would have been totally excluded from surgery.
In the literature, however, some issues are still being
debated. A major issue is about the strategies of pre-
vention of dangerous neurological complications such as
perioperative stroke and paraplegia. Another important
topic regards the need to revascularize the left subcla-
vian artery in case of intraoperative coverage with 
Introduction
Since the publication of Dake and Coll. 1, in the last
twenty years, the endovascular techniques have totally
revolutionized the treatment of aortic diseases, especial-
ly in the thoracic region. 
On one hand, the endovascular techniques are now uni-
versally recognized as the gold standard for the treat-
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proximal landing zone of the endograft. Eventually, the
reintervention rate in the long term is the Achilles heel
of TEVAR, similarly to what happens for the abdomi-
nal aortic district 4. To contribute to a better under-
standing of these issues, it is important to report the
real clinical experience, which could be useful in the dai-
ly practice.
Aim of the study was to report our “real-world” retro-
spective and monocentric experience of patients under-
going endovascular exclusion of thoracic and thoraco-
abdominal aortic lesions from May 2002 to May 2015.
Materials and Methods
Ethics approval was obtained from our Institution.
We retrospectively reviewed data of all consecutive
patients who underwent endovascular exclusion of either
a thoracic or a thoraco-abdominal aortic lesion from May
2002 to May 2017 in our institution.
Data were obtained through a retrospective research on
medical records and patients’ radiological imaging. For
each patient we considered preoperative data (such as
demographics, information about the aortic disease,
comorbidities), intraoperative data and complications at
30 days and in the long term. Follow-up information
were collected through the review of outpatient visits
and telephonic interview.
All patients underwent a preoperative angio-computed
tomography (angio-CT) scan of the thoraco-abdominal
aorta, which was mandatory for the correct pre-proce-
dural planning. A duplex ultrasound scan of supra-aor-
tic vessels was performed in all cases (except for emer-
gent procedures) to assess carotid, vertebral and subcla-
vian artery patency and flow, especially in case of aor-
tic dissection. 
All procedures were performed by vascular surgeons in
the operating theatre. 
For the prevention of spinal cord ischemia (SCI), a cere-
brospinal fluid drainage (CSFD) was positioned by the
anesthesiologist at least 1 hour before the procedure in
selected patients, such as in case of previous aortic
surgery, when there was the need to cover a long seg-
ment of aorta (>30 cm), when the aortic endograft would
cover the region between T8 and L1, or when there was
the need to cover the left subclavian artery (LSA)5. The
CSFD was usually removed at least 48 hours after the
procedure when there were no signs of SCI. Otherwise,
it was left in place as indicated by the neurologist.
Drainage of the CSF was performed when the liquoral
pressure was higher than 15 mmHg.
The LSA was kept patent whenever possible. When the
coverage of the LSA was necessary for the achievement
of a proper proximal landing zone of the endograft, how-
ever, elective pre-procedural or intra-procedural revascu-
larization was performed in selected cases, such as young
patients, when there was no adequate collateral flow from
the contralateral vertebral artery or the hypogastric arter-
ies, or in case of previous aortic-iliac surgery. The revas-
cularization was obviously mandatory in presence of a
hemodialytic arterial-venous fistula or a coronary artery
bypass graft with left internal mammary artery6. In case
of landing of the proximal edge of the endograft in either
zone 0 or zone 1 (Ishimaru’s classification), a rapid
sequence pacing was used to facilitate the precise place-
ment of the graft itself.
After treatment all patients were discharged on
antiplatelet therapy (either ASA 100 mg daily or
Clopidogrel 75 mg daily all lifelong) unless they were
already on anticoagulant therapy for preoperative comor-
bidities.
All collected data were inserted in a database and ana-
lyzed as appropriate. 
Patients were grouped according to the different etiology
of the aortic lesions: atherosclerotic thoracic aneurysms
(TAA) or thoraco-abdominal aneurysms (TAAA) and
floating thrombus were gathered in group A; acute com-
plicated type B dissection (TBD), penetrating aortic ulcers
(PAU) and intra-mural hematomas (IMH)  in group B;
chronic TBD evolving in TAA in group C; traumatic
injuries in group D. Mortality, reinterventions and occur-
rence of neurological complications, both at 30 days and
in the long term, were analyzed as primary outcomes,
with respect to the different type of pathology. Secondary
outcomes were the occurrence of post-implantation syn-
drome (PIS) and of left arm ischemia in patients in
whom the left subclavian artery was intraoperatively cov-
ered by the endograft without elective revascularization.
Statistical analysis was performed using the software
JMP® 5.1.2 (SAS Institute, Inc., Cary, NC, USA). The
data were reported as median and interquartile ranges
(IQR) for variables with non-Gaussian distribution
(Shapiro-Wilk test) and mean ± 2SD for Gaussian vari-
ables. Categorical variables were presented as n (%).
Kaplan-Meier method was used to estimate survival, free-
dom from neurological events and freedom from rein-
terventions. The Wald test was performed to assess if
age could affect the raw survival. Chi-square test (Pearson
correlation), logistic regression and One-way ANOVA
were used as appropriate to assess any possible factor
which could affect outcomes. P values <.05 were con-
sidered statistically significant. When a correlation was
found, the strength of the correlation was reported
through R2.
In case of any statistically significant results, ROC curves
were also analyzed for the determination of cut-off val-
ues which could be highly associated with the occur-
rence of follow-up events. 
Results
From May 2002 to May 2017 a total of 94 patients
(74 males, 78.7%), median age 73 years (IQR 68-79
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years) were treated consecutively for either a thoracic or
a thoraco-abdominal aortic lesion. 
In particular, 63 patients underwent thoracic endovas-
cular aortic repair (TEVAR) for either an atherosclerot-
ic TAA or an aortic floating thrombus (group A, see
Table I). Of them, 6 TAA had been symptomatic for a
contained rupture, 4 TAA had either hemophtoe or dys-
phonia (2 patients each) and 5 had been symptomatic
for chest pain. One patient who had an aortic floating
thrombus presented with bilateral acute lower limb
ischemia. Five more patients of group A underwent a
total endovascular exclusion of a thoraco-abdominal
aneurysm (4 type II according to Crawford’s classifica-
tion and one type IV) using a fenestrated endograft in
3 patients. A multilayer flow modulator stent-graft was
employed for “compassionate use” in 2 patients who
were excluded from other treatments because of high
surgical risk and hostile anatomy. 
For patients with aortic aneurysms, the median diameter
of the lesion was 65 mm (IQR 60-79.5; range 30-93). 
Group B included 3 patients who presented with chest
pain and IMH, 11 PAU (being 2 of them symptomatic
for chest pain) and 6 patients who underwent TEVAR
for an acute complicated TBD which caused either acute
limb/visceral ischemia (5 patients) or irrepressible chest
pain (1 patient).
Four patients underwent TEVAR for a chronic TBD
(type IIIA according to De Bakey’s classification) evolv-
ing into TAA with an aortic diameter greater than 50
mm (Group C), and 2 patients were treated for a trau-
matic rupture at the isthmus (Group D).
As described in Table I, patients mainly had a history
of hypertension. Fourteen patients had a concomitant
infrarenal abdominal aortic aneurysm (AAA) which was
under regular follow-up, while 32 had already under-
gone either endovascular or open aortic repair of an AAA
(4 patients and 28 patients respectively).
At preoperative anesthetic assessment, most of the patients
was in ASA (American Society of Anesthesiologists) class
3 (55.7%) and 4 (30%).
Technical success, defined as the correct deployment of
the endograft without any immediate endoleak, was
achieved in 96.8% of the cases overall. In 2 patients of
group A, a type Ia endoleak at the end of the proce-
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TABLE I - Characteristics of the patients
n=94
Male Sex 74 (78.7%)
Median Age, years (IQR) 73 (68 – 79)
Etiology of the lesion
Group A:
Atherosclerotic TAA 59 (62.7%)
Atherosclerotic TAAA 5 (5.3%)
Aortic floating thrombus 2 (2.1%)
Group B:
Complicated acute Type 6 (6.4%)
B dissectionPAU 11 (11.7%)
IMH 3 (3.2%)
Group C:
Chronic type B dissection evolving in TAA 4 (4.2%)
Group D:
Post-Traumatic lesion 2 (2.1%)
Comorbidities
Current or previous smoke 38 (40.4%)
COPD 33 (3.1%)
CAD 29 (30.8%)
Hypertension 78 (83%)
Dyslipidemia 48 (51.1%)
Diabetes 12 (12.8%)
Chronic renal failure 41 (43.6%)
Previous neoplasm 18 (19.1%)
Stroke 1 (1.06%)
Transient Ischemic Attack 2 (2.1%)
Concomitant AAA 14 (14.9%)
Previous AAA repair 32 (34%)
Emergent setting 15 (15.9%)
Legend: TAA = Thoracic Aortic Aneurysm; TAAA = Thoraco-
Abdominal Aortic Aneurysm; PAU = Penetrating Aortic Ulcer; 
IMH = IntraMural Hematoma; COPD = Chronic Obstructive
Pulmonary DiseaseCAD = Coronary Artery Disease; AAA =
Abdominal Aortic Aneurysm
TABLE II - Intraprocedural and in-hospital data (Mean+SD; Median,
IQR)
n=94
Anesthesia
General 74 (78.7%)
Local + conscious sedation 3 (3.2%)
Locoregional 17 (18.1%)
Vascular Access
Surgical femoral 82 (87.3%)
Abdominal aorta 7 (7.4%)
Surgical Iliac 5 (5.3%)
Percutaneous brachial (additional) 12 (12.7%)
Percutaneous contralateral femoral (additional) 27 (28.7%)
CSF drainage 27 (28.7%)
Trans-esophageal echocardiography 16 (17%)
LSA coverage 18 (19.1%)
Time of operation (min; median, IQR) 105 (70-140)
Amount of contrast (cc) 45.2 + 1.5
Fluoroscopy time (min) 34.3 + 1.6
Blood loss (cc) 143 + 12
Proximal landing zone (Ishimaru’s class)
Zone 0 1 (1.1%) 
Zone 1 1 (1.1%) 
Zone 2 18 (19.1%) 
Zone 3 24 (25.5%)
Zone 4 50 (53.2%)
Total endograft length (median, IQR) 130 mm
(125-180 mm)
Length of stay (days; median, IQR) 6 (4-8)
ICU (days; median, IQR); 4 (2-6)
Legend: LSA = Left subclavian artery; CSF = cerebro-spinal fluid 
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dure was immediately corrected with a proximal cuff,
with good results. In the latter case, the procedure was
interrupted for the occurrence of a severe ischemic stroke
of the posterior cerebral circulation during the delivery
of the graft for the repair of a TAA. The patient was
then immediately referred to the ICU and died after 28
days.
As described in Table II, the procedures were manly per-
formed using general anesthesia (78.7%).
A CSFD was selectively used in 27 patients (being all
5 cases of TAAA, 1 case of acute complicated TBD, all
6 cases of chronic TBD and 15 cases of TAA). The
CSFD was left in place for a median of 50 hours (IQR
48-56 hours). In 7 of these cases, active drainage was
performed because the liquoral pressure rose up to more
than 15 mmHg.
Endovascular repair was performed via surgical femoral
access in 82 patients, while in the remaining 12 cases a
different vascular access was needed, due to the presence
of either small or highly calcified femoral-iliac arteries
(Table II). A percutaneous transluminal angioplasty or
femoral arterectomy was necessary in 11 patients before
the endograft could be successfully delivered. An addi-
tional percutaneous femoral or percutaneous brachial
access was performed for the diagnostic angiography in
27 and 12 patients respectively. In particular, a percu-
taneous brachial access was used in the 3 patients who
underwent the endovascular exclusion of TAAA using
the fenestrated endografts, in all cases of acute TBD and
in 3 cases of chronic TBD.
According to Ishimaru’s classification (Fig. 1), the prox-
imal landing zone for the endograft was mainly 3 and
4 (24 and 50 patients respectively). The LSA was inten-
tionally covered in 20 patients (all of them in group A),
6 of whom underwent elective revascularization due to
either previous aortic surgery or young age (3 patients
each). In 2 cases, the flow to the LSA was restored
through a left common carotid artery (LCCA)-to-LSA
prosthetic bypass graft (Dacron). In one of these patients,
also LCCA was covered to achieve a proper proximal
landing zone for the endograft (Ishimaru’s zone 1), so
both LCCA and LSA were revascularized using a pros-
thetic right common carotid artery (RCCA)-to-LCCA-
to-LSA bypass graft. In the remaining case, the lesion
involved the aortic arch so the endograft was placed with
a proximal land in Ishimaru’s zone 0 after a total
debranching of the supra-aortic trunks and reconstruc-
tion on the ascending aorta had been performed through
sternotomy.
A single endograft was used in 78 cases, 2 endografts in
14 patients and 3 endografts in one patient, with a medi-
an length of covered aortic region of 130 mm (IQR
125-180 mm, range 50-430 mm).
A Bolton RelayTM tubular graft was mostly used (Table
III). The five thoraco-abdominal aneurysms were exclud-
ed using a Cardiatis Multiflow Modulator Stent in 2 cas-
es and a Cook Z-Fen in the remaining 3 cases (Fig. 2).
Post-procedural median length of stay (LOS) was 6 days
(IQR 4-8 days, range 0-31). Intensive Care Unit (ICU)
stay was needed in 22 cases, with a median length of
stay of 4 days (IQR 2-6 days, range 2-28 days).
Overall median follow-up was 25.6 months (range 1 –
97.7 months).
THIRTY-DAYS COMPLICATIONS
Mortality
Five patients of group A died within 30 days (5.3%).
The first was an 88-years-old man who arrived at
Emergency Department for a contained rupture of a tho-
racic aneurysm. He immediately underwent the endovas-
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Fig. 1: Ishimaru’s classification of aortic arch and thoracic aorta.
TABLE III - Type of endografts used in our series
Type of endograft N (%)
Relay Bolton 50 (53.7%)
Gore Tag 8 (8.6%)
Endomed Endofit 2 (2.1%)
Cook TX2 17 (18.3%)
Cook Z-FEN 3 (3.2%)
Medtronic Valiant 7 (7.5%)
Jotec E-Vita 5 (5.4%)
Medtronic Talent 1 (1%)
Cardiatis MFM 2 (2.1%)
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cular repair but a cardiopulmonary arrest occurred in the
following 24 hours. 
The second patient (a 77 female) died for a visceral
ischemia in postoperative day (POD) 1 after an emer-
gent exclusion of a thoracic aneurysm which had been
symptomatic for hemophtoe and thoracic pain.
The third death was caused by a severe ischemic stroke
of the posterior cerebral circulation which occurred intra-
operatively during the delivery of the graft. The patient
was then immediately referred to the ICU and died after
28 days.
The fourth case of death was recorded after a frontal
stroke which occurred in POD 2nd in a 86-years-old
male patient who underwent endovascular exclusion of
a thoracic aneurysm.
The last patient died for a congestive heart failure 10
days after he had been discharged. He had undergone
elective endovascular exclusion of a thoracic aneurysm.
No more deaths were recorded within 30 days among
the remaining groups.
Neurological complications
There were 5 (5.3%) neurological complications in group
A, being 2 cases of major strokes and 3 cases of SCI.
The two strokes (one frontal and one in the posterior
cerebral circulation) occurred in POD 2nd and intraop-
eratively respectively, both of them leading to death (see
“Thirty-days mortality”). 
One of the three cases of SCI completely resolved 48
hours later after CSFD and administration of corticos-
teroids, while the remaining two required prolonged
spinal rehabilitation but eventually the paraplegia com-
pletely resolved respectively after 4 and 8 months.
The occurrence of perioperative stroke was related to the
presence of a symptomatic aortic lesion (P=.02; R2=0.24).
It was also more frequent in older patients (P=.05;
R2=0.004) with a higher probability in patients older than
86 years (AUC 97% at ROC curve analysis). There was
no evidence of any correlation with preoperative comor-
bidity or with the intraoperative coverage of the LSA.
As regards the risk of SCI, it was associated with the
length of covered aortic segment (P=.007; R2=0.0039),
being a greater risk of SCI for covered segment longer
than 230 mm (AUC 94%). The occurrence of SCI on
the other side did not seem to be affected by the pres-
ence of CSFD, the coverage of the LSA or a previous
abdominal aortic surgery.
There were also two cases of post-dural puncture
headache, which resolved with hydration, analgesia and
administration of corticosteroid therapy.
No neurological complications occurred postoperatively
in group B, C and D.
Reinterventions
A total of 6 patients in group A required 6 procedures.
One patient with TAA required an emergent correction
of a type Ia endoleak in POD 3rd for distal migration
of the endograft. A second patient underwent a left tho-
racotomy for a hemothorax following an emergent
endovascular exclusion of a ruptured TAA. A LCCA-to-
LSA bypass was required in a third patient with TAA
for the occurrence of a subacute left arm ischemia, the
fourth patients underwent an evacuation of hematoma
of the femoral access. An exploratory laparotomy was
performed in POD 1st in a woman who developed
intestinal ischemia due to possible embolism. The
remaining patient underwent a Fogarty embolectomy for
acute lower right limb ischemia due to thrombosis of
the femoral access.
Postoperative course was uneventful in the remaining
groups. In particular, symptoms disappeared in all
patients who underwent TEVAR for acute complicated
TBD. In these latter patients, an angio-CT scan at dis-
charge showed the complete thrombosis of the false
lumen with regular patency of the visceral and renal ves-
sels in all cases.
LONG-TERM COMPLICATIONS
Mortality
Survival in group A was 87 %± 3.7% and 62.8%±6.3%
at 1 and 5 years respectively (Fig. 3), which was sig-
nificantly affected by age (P=.004), history of renal fail-
ure (P=.005) and history of coronary artery disease
(P=.02). In particular, in patients affected by chronic
renal failure, a preoperative serum creatinine level more
than 1.22 mg/dL seemed to be a predictive factor for
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Fig. 2: Endovascular treatment of thoraco-abdominal aneurysm using
a Cardiatis Multiflow Modulator Stent (A, on the left side) Cook
Z-Fen (B, on the right side).
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long-term mortality (ROC curve, AUC 65%). In patients
treated for aneurysmal disease, a preoperative sac diam-
eter greater than 70 mm (ROC curve, AUC 69%) also
seemed to be a predictive factor for mortality.
Deaths in the long-term were not aortic-related and no
aortic rupture were detected during follow-up. There was
no deaths in the long-term among the remaining groups
of patients.
G. Nano, et al.
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Fig. 3: Kaplan-Meier analysis with estimated long-term raw survival
of group A.
Figure 4. Kaplan-Meier analysis with estimated long-term freedom
from reintervention of group A.
TABLE IV - Details of reinterventions at long term
Group Patient Primitive Time of reintervention Cause Type
(sex, age) Patology (postop months) of reintervention of reintervention
A Male 69 y.o. TAA 3 Endoleak Ia Debranching + proximal cuff
A Male 72 y.o. TAA 50 Distal dilatation à Endoleak Ib Distal cuff
A Male 79 y.o. TAA 53 Endoleak Ia Debranching + proximal cuff+Plug in LSA
A Male 71 y.o. TAA 2 Retrograde dissection Debranching + proximal cuff
A Male 82 y.o. TAA 10 Endoleak Ia Proximal cuff
A Male 63 y.o. TAA 47 Endoleak Ia Proximal cuff
A Male 84 y.o. TAA 4 Endoleak Ia Debranching + proximal cuff
A Male 63 y.o. TAA 39 Endoleak Ia Ascending aorta prosthetic replacement
A Male 74 y.o. TAAA 10 Endoleak Ia + Ib Proximal and distal cuff
A Male 65 y.o. TAA 38 Distal dilatation → Endoleak Ib Distal cuff
A Male 65 y.o. TAA 58 Distal dilatation → Endoleak Ib Distal cuff
A Male 76 y.o. TAA 26 Endoleak II Plug in LSA
A Male 78 y.o. TAA 28 Endoleak Ib Distal cuff
A Male 80 y.o. TAA 25 Endoleak Ib Distal cuff
A Male 72 y.o. TAA 12 Endoleak Ib Distal cuff
A Male 84 y.o. TAAA 34 Endoleak Ia + Ib Proximal and distal cuff
A Male 70 y.o. TAA 39 Endoleak Ia Proximal cuff
A Male 81 y.o. TAA 3 Endoleak Ia Proximal cuff
A Male 71 y.o. TAA 2 Left arm claudication LCCA to LSA bypass
A Male 64 y.o. TAA 3 Left arm claudication LCCA to LSA bypass
B Male 67 y.o. PAU 58 Endoleak Ia Proximal cuff
B Male 63 y.o. Acute Complicated TBD 2 Renal malperfusion Renal artery angioplasty
D Male 53 y.o. Traumatic rupture 7 Endoleak Ia Proximal cuff
D Male 40 y.o. Traumatic rupture 5 Infolding Relining
Legend: y.o. = years old; TAA = thoracic aortic aneurysm; LSA = left subclavian artery; PAU = penetrating aortic ulcer; TBD = type
B dissection; TAAA = thoraco-abdominal aneurysm; LCCA = left common carotid artery
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Neurological complications
Three more strokes were recorded in the long term only
in group A. They did not seem to be affected by any
preoperative neither intraprocedural factors. Not any oth-
er neurological complications were recorded in the
remaining groups.
Reinterventions
Freedom from reinterventions in group A (Fig. 4) was
79.7%±4.6% and 54.7%±7.6% at 1 and 5 years respec-
tively, being significantly affected by the coverage of the
LSA (P= .03). Reinterventions were also more likely to
occur in patients who underwent an urgent procedure
(P=.04). 
Two out of the 5 patients who underwent TEVAR for
TAAA required a reintervention in the long-term (Table
IV), in particular both patients in whom the Cardiatis
Multi-Flow Modulator stent was used. The Cook TX2
endograft (P= .01) and the Cardiatis MFM (P=.02)
endoprostheses were more associated with the occurrence
of reinterventions.
In patients affected by aneurysmatic lesions, a diameter
greater than 67mm seemed to be a predictive factor for
the need of secondary procedures (ROC curve, AUC
64%).
One patient of group B required a renal angioplasty
(Table IV) because of a severe stenosis with renal malper-
fusion due to the remodeling of the thrombosed false
lumen. In fact, the intimal flap at the time of presen-
tation involved the origin of the renal artery. Another
patient who was treated for a PAU developed a type Ia
endoleak after 58 months, due to aneurysmal evolution
of the aortic region just at the proximal end of the graft.
A proximal cuff was then placed, with optimal results.
In the patients of group B treated for acute TBD, the
false lumen was completely excluded and no aneurysmal
evolution of the aorta was recorded.
No reinterventions were needed in the long-term for
patients of group C. In particular, a shrinkage of the
aneurysmal sac was observed in all cases.
Both patients of group D required a reintervention for
either a type Ia endoleak or a graft infolding7 (1 patient
each, Table IV).
The main cause for a reintervention was the occurrence
of a type I endoleak (a total of 18 patients, Table IV).
Five more endoleaks occurred in the long term in group
A, being 4 type II endoleaks (1 from a covered LSA,
which required the placement of a plug in the LSA, and
3 from intercostal arteries, which are still under surveil-
lance) and a type V endoleak which is still in follow-
up. In patients treated for aneurysmal disease, an
endoleak of any type was more likely to occur when the
preoperative sac diameter was greater than 86 mm (ROC
curve, AUC 70%). 
POST-IMPLANTATION SYNDROME (PIS)
A total of thirty-seven patients out of 94 (39.4%) expe-
rienced a postoperative fever, which lasted for a median
of 3 days (IQR 2-4 days; range 1-11 days) and with a
median body temperature of 38.5°C (IQR 38-38.8°C;
range 37.7-39.5°C). However, a real PIS as described for
EVAR7 was not detected, as white blood cells count did
not raise significantly. Irrespectively from the etiology of
the disease, fever occurred most frequently in men 
(P= .01, R2=0.04), which was probably due to the high-
er prevalence of male patients in our series. 
LEFT ARM ISCHEMIA
Two of the 14 patients (14.3%) in whom LSA was cov-
ered without elective revascularization reported a left arm
ischemia within 30 days. The former patient (a 82 years-
old woman with an asymptomatic TAA), experienced
paresthesia and mild hypothermia of her left arm in
POD 2nd, which spontaneously resolved after medical
therapy with prostanoid. The latter patient (a 58 years-
old male who underwent emergent exclusion of a symp-
tomatic TAA) had a claudication of his left arm and in
POD 18th underwent a LCCA-to-LSA bypass graft.
In the long-term, two more patients in whom the LSA
was intraoperatively covered by the endograft without
elective revascularization required a LCCA-to-LSA bypass
for a left arm severe claudication which occurred respec-
tively two and three months after the first procedure. 
Coverage of the left subclavian artery was the only fac-
tor which significantly affected the occurrence of left arm
ischemia (P=.0001, R2 0.41).
Discussion
In the last twenty years, the endovascular techniques have
totally revolutionized the treatment of aortic diseases,
especially in the thoracic region, overcoming the open
techniques with the advantage of reduced postoperative
mortality and morbidity2. In our real-world experience,
the endovascular techniques allowed the treatment of a
wide variety of aortic pathologies, ranging from athero-
sclerotic TAA, to acute and chronic TBD, traumatic
lesions and even 5 patients with TAAA. Each and every
type of pathology has its pro’s and con’s towards
TEVAR, and this was the main reason why results were
reported taking into account the different etiology of the
lesion. Irrespectively of the kind of the aortic disease,
however, a proper preoperative selection of the patient
is mandatory, to optimize the long-term benefit survival
of TEVAR.
In our study, the long-term survival after TEVAR for
aneurysmal atherosclerotic disease was influenced by
comorbidities such as coronary artery disease and 
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chronic renal failure. The latter is in fact a well-known
predictive factor for mortality after TEVAR 9. In our
series, mortality was also affected by the preoperative
diameter of the sac in patients undergoing treatment for
aneurysms. This variable could be linked to the severity
of both the aortic pathology and the cardiovascular
comorbidities, as it was reported for patients undergo-
ing endovascular repair for infrarenal aortic aneurysm 10.
There weren’t any predictive factors of mortality in the
other groups, as numbers were too low to allow a prop-
er statistical analysis.
The risk of neurological complication after TEVAR is
another major topic, in particular concerning the risk of
stroke and SCI.
As regarding the risk of perioperative stroke, Sullivan
and Stundt reported an incidence of stroke after TEVAR
of 2.2% 11, which was higher in patients with a histo-
ry of renal failure or previous cerebrovascular events 12,
an excessive intraoperative manipulation of devices with-
in the aortic arch, a prolonged operative time, when
there was the need to cover the LSA or in case of
debranching of supra-aortic trunks.
Our results compared favorably with those reported in
the Literature. In our analysis, albeit limited by the small
sample size, the occurrence of postoperative stroke in
patients of group A was affected by age, especially in
patients older than 86 years, and by the presence of pre-
operative aortic symptoms.
The incidence of SCI following TEVAR is estimated at
around 3-5%, depending on the studies 5. The main risk
factors for this complication have been identified in the
concomitant or previous surgery of the abdominal aorta,
in the history of acute dissection or aneurysm rupture, in
the extensive coverage in the thoraco-abdominal aorta with
the graft, in the coverage of the LSA, in the history of
chronic renal failure and in the history of diabetes. Also
hemodynamic factors such as systolic hypotension and
perioperative anemia seemed to play an important role in
the occurrence of SCI 5. Among the strategies for pre-
vention of SCI, the use of CSFD in TEVAR is still under
discussion, without any unequivocal conclusion 13,14.
According to Hiratzka and Coll., placement of CSFD is
recommended in selected patients deemed to be at high
risk of SCI 15. In our results we did not found a sig-
nificant difference in the occurrence of SCI between
patients with CSFD and those without. The only risk fac-
tor which significantly affected the occurrence of this com-
plication was the total length of the prosthetic coverage,
with a cutoff of 230 mm above which the risk seemed
to be significantly increased. For these reasons, in our
experience the prevention strategies of SCI include:
– selective placement of CSFD in high risk patients;
– a two-staged treatment of extensive aortic lesions (as
for thoraco-abdominal aneurysms) to allow for an
enhancement of collateral circulation;
– maintaining an adequate blood volume, hemoglobin
and mean arterial pressure (greater than 90mmHg);
– close monitoring of the motility of the lower limbs.
A third major issue regards the risk of reintervention
and endoleaks in the long term and strategies aimed at
reducing their frequency. Reintervention and endoleaks
are closely related, being the latter the main cause for
reinterventions, as it was in our series.
In our experience, the type of endograft seemed to play
an important role in the occurrence of reinterventions
during follow-up, in particular with a stronger correla-
tion when either Cook TX2 or Cardiatis MFM endo-
prostheses were used.
We tried to explain this finding by analyzing the tech-
nical features of these grafts. The first version of the
Cook TX2, was not so conformable to the aortic arch
curvature and many studies in the literature showed that
over the years the first stent could detach from the inner
curvature, causing the so-called “bird-beak” effect 16 and
consequently leading to type Ia endoleaks. The new deliv-
ery system, along with changes of the graft itself, have
made the device more conformable to the anatomy. 
The Cardiatis MFM, on the other side, showed a low
compliance to the native aorta and a tendency to shrink
after release, with consequent loss of sealing and the need
for secondary procedures in both patients of our series,
who underwent endovascular correction of type Ia and
Ib endoleaks.
In our experience reinterventions occurred also more fre-
quently in case of urgent aortic repair and in all cases
of traumatic etiology of the disease. One of the possi-
ble explaining for these correlations could be the fact
that usually the aortic repair for traumatic injuries is per-
formed in an emergent setting 17, without a precise pre-
operative planning. Moreover, the low blood pressure
that often accompanies the patient, could represent a
bias in the measurement of aortic diameters on CT
angiography, underestimating the real size and conse-
quently leading to an excessive oversizing of the graft.
Furthermore, an emergent aortic repair usually aims to
stabilize the patient’s life, leaving possible cause of sec-
ondary minor procedures to a later time. Finally, most
endografts have been developed for the treatment of
degenerative aortic diseases such as aneurysms and dis-
sections, with large diameters and poor conformability
which do not adapt to a young and otherwise healthy
aorta, with an increased risk of either infolding of the
graft or dilation of the native vessel 18 and consequent
occurrence of endoleaks and migration of the device.
POST-IMPLANTATION SYNDROME (PIS)
The occurrence of fever after endograft implantation
despite antimicrobial therapy, together with leukocytosis
(WBC>12,000/mm3) and the raise of inflammatory
markers without any evidence of infection 19 is known
in the literature as post implantation syndrome (PIS). 
This clinical entity has been widely described after EVAR
G. Nano, et al.
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using particular kinds of abdominal endografts 8, but lit-
tle has been reported after TEVAR so far. Akowuah and
Coll. 20 reported the occurrence of an inflammatory
response after TEVAR but without the presence of a
leukocytosis more than 12.000 WBC/mm3, as request-
ed for the definition of PIS.
In our series also, the occurrence of early post-proce-
dural systemic inflammatory response did not correspond
closely to the definition of PIS, as described for EVAR.
MANAGEMENT OF LSA
The management of the LSA when covered during
TEVAR has been an issue of great controversy in the
Literature.
In support of a routine revascularization, Zamor and
Coll. 21 reported a significant reduction in perioperative
rates of stroke upper limb ischemia in patients with pre-
vious revascularization than in those without.
Furthermore, in the EUROSTAR registry 22 the cover-
age of the LSA without previous revascularization (along
with the total length of the prosthetic implant) was iden-
tified as a risk factor for SCI.
Authors who perform a selective revascularization of the
LSA argue that the coverage of the vessel does not
increase significantly the risk of neurological complica-
tion or upper limb ischemia, while revascularization is
not free from complications itself 23.
In our series, the coverage of the LSA did not affect the
occurrence of neurological complications at 30 days.
Nevertheless it was found to be the only factor affect-
ing the occurrence of left arm ischemia. 
Considering our findings and data reported in the liter-
ature, our policy regarding the management of the LSA
aims to avoid its coverage whenever possible. Otherwise,
revascularization is performed selectively. In case of occur-
rence of left arm ischemia, postoperative revascularization
can be performed without any particular complications.
In conclusion, in our experience, the endovascular repair
of either thoracic or thoraco-abdominal aortic lesions was
a safe and effective technique, with acceptable mortality
and neurological complication rates, both at 30 days and
in the long term. 
Mortality after TEVAR for either atherosclerotic aneurys-
mal disease or floating thrombus was significantly affect-
ed by age and a history of either renal failure or coro-
nary artery disease. In group A, the occurrence of post-
operative stroke was affected by age, especially in patients
older than 86 years, and by the presence of preopera-
tive aortic symptoms. The occurrence of early postoper-
ative SCI was affected by the total length of the pros-
thetic coverage. 
Reintervention in the long term occurred more fre-
quently after endovascular repair of either TAAA or trau-
matic injuries, and were mainly required for a type I
endoleak. 
A post-implantation syndrome was not clearly detected. 
Coverage of the left subclavian artery significantly affect-
ed the occurrence of left arm ischemia, irrespectively
from the type of the aortic disease, but not the occur-
rence of SCI.
Conclusion
The endovascular repair of thoracic/thoraco-abdominal
aortic lesions had acceptable mortality and neurological
complication rates, both at 30 days and in the long term.
Reinterventions in the long term occurred more fre-
quently after TAA/TAAA and traumatic injuries, and
were mainly required for a type I endoleak.
Riassunto
Riportiamo la nostra esperienza nel trattamento endovas-
colare delle lesioni dell’aorta toracica e toraco-addomi-
nale nei pazienti consecutivamente sottoposti ad inter-
vento da maggio 2002 a maggio 2017.
I dati relativi ai suddetti pazienti sono stati raccolti in
un database in maniera retrospettiva, analizzati e divisi
in 4 gruppi: aneurismi aterosclerotici dell’aorta toracica
e toraco-addominale (AAT/ATA) e trombi flottanti
(gruppo A); dissezioni acute complicate di tipo B (TBD),
ulcere penetranti aortiche (PAU) ed ematomi intramu-
rali (IMH) nel gruppo B; dissezioni croniche con
evoluzione aneurismatica (gruppo C); lesioni traumatiche
(gruppo D).
Per ogni gruppo sono stati analizzati come outcomes pri-
mari la mortalità, il tasso di reinterventi e l’insorgenza
di complicanze neurologiche, sia a 30 giorni ed a lun-
go termine.
Il 55.3% dei 94 pazienti presi in esame sono stati sot-
toposti ad intervento per AAT. Eventi come mortalità a
30 giorni e complicanze neurologiche sono stati osser-
vati solamente per il gruppo A (5 casi per ciascun indi-
catore, 5.3%).
Considerando il gruppo A, sei pazienti sono stati sotto-
posti a reintervento (6.4%), mentre la sopravvivenza a 5
anni è stata del 62.8%+6.3% e la libertà da complicanze
neurologiche del 88.3%+4.2%. Nei restanti gruppi non
sono stati registrati né decessi né complicanze neuro-
logiche. Non si sono verificate rotture aortiche tardive.
E’ stato registrato un tasso di libertà da reinterventi a 5
anni del 54.7%+7.6% nel gruppo A, mentre almeno un
reintervento è stato necessario per ciascun paziente del
gruppo D. Tra tutte, la principale causa di reintervento
è stata l’occorrenza di un endoleak di tipo I.
Questi dati confermano come la correzione endovasco-
lare delle lesioni dell’aorta toracica e toraco-addominale
sia gravata da tassi di mortalità e complicanze neuro-
logiche accettabili, sia a 30 giorni che nel lungo termine.
Nel lungo termine sono stati sottoposti a reintervento più
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frequentemente i pazienti affetti da AAT/ATA e lesioni
traumatiche, principalmente per endoleak di tipo I.
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